Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway
Open Access
- 1 December 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 5 (12), 3303-3311
- https://doi.org/10.1158/1535-7163.mct-06-0154
Abstract
Although chemotherapy treatment is associated with an increased risk of thrombosis, the pathogenic mechanisms for the thrombogenic effect of chemotherapeutic drugs are poorly understood. We hypothesize that exposure of vascular endothelial cells to chemotherapeutic agents results in the loss of a thromboresistant phenotype. In this study, we examined the effects of the chemotherapeutic agent doxorubicin on the endothelium-based protein C anticoagulant pathway. The endothelial cell protein C receptor (EPCR) and thrombomodulin are two endothelial cell surface receptors required for the conversion of zymogen protein C to the anticoagulant enzyme activated protein C. Exposure of human umbilical vein endothelial cells (HUVEC) to doxorubicin resulted in a dose- and time-dependent decrease in cell surface EPCR levels. This decrease occurred as a result of receptor shedding as well as from a down-regulation in EPCR mRNA levels. In contrast, doxorubicin treatment of HUVECs resulted in a dose- and time-dependent increase in cell surface thrombomodulin attributed to an up-regulation of thrombomodulin mRNA levels. The net effect of the doxorubicin-induced changes in EPCR and thrombomodulin levels was a decrease in the capacity of HUVECs to convert protein C to activated protein C. Preliminary studies suggest that doxorubicin free radical metabolites mediate the doxorubicin-induced changes in EPCR expression but not those of thrombomodulin expression. In summary, these results suggest that doxorubicin alters the hemostatic balance of endothelial cells by down-regulating the endothelium-based protein C anticoagulant pathway. [Mol Cancer Ther 2006;5(12):3303–11]Keywords
This publication has 45 references indexed in Scilit:
- A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosisBlood, 2004
- Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerAnti-Cancer Drugs, 2003
- The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illnessCritical Care, 2001
- The protein C pathwayCritical Care Medicine, 2000
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- The Endothelial Cell Protein C ReceptorPublished by Elsevier BV ,1996
- Presence of Functional Cyclic AMP Responsive Element in the 3′-Untranslated Region of the Human Thrombomodulin GeneBiochemical and Biophysical Research Communications, 1994
- The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast CancerNew England Journal of Medicine, 1988
- Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycinBiochemical and Biophysical Research Communications, 1977
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970